NEXT Financial Group Inc Has $678,000 Stake in Eli Lilly and Co (LLY)
NEXT Financial Group Inc lowered its stake in shares of Eli Lilly and Co (NYSE:LLY) by 38.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,029 shares of the company’s stock after selling 4,961 shares during the quarter. NEXT Financial Group Inc’s holdings in Eli Lilly and were worth $678,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Dynamic Advisors Solutions LLC increased its position in shares of Eli Lilly and by 3.0% during the 2nd quarter. Dynamic Advisors Solutions LLC now owns 5,868 shares of the company’s stock valued at $483,000 after purchasing an additional 171 shares during the last quarter. Atria Investments LLC increased its position in shares of Eli Lilly and by 10.2% during the 2nd quarter. Atria Investments LLC now owns 44,057 shares of the company’s stock valued at $3,626,000 after purchasing an additional 4,078 shares during the last quarter. Iberiabank Corp increased its position in shares of Eli Lilly and by 50.4% during the 2nd quarter. Iberiabank Corp now owns 36,252 shares of the company’s stock valued at $2,984,000 after purchasing an additional 12,150 shares during the last quarter. Private Trust Co. NA increased its position in shares of Eli Lilly and by 9.4% during the 2nd quarter. Private Trust Co. NA now owns 8,518 shares of the company’s stock valued at $700,000 after purchasing an additional 731 shares during the last quarter. Finally, New England Research & Management Inc. bought a new position in shares of Eli Lilly and during the 2nd quarter valued at approximately $354,000. 76.35% of the stock is currently owned by hedge funds and other institutional investors.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the completion of the sale, the senior vice president now owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The disclosure for this sale can be found here. Insiders sold a total of 251,088 shares of company stock valued at $22,041,236 over the last quarter. Company insiders own 0.20% of the company’s stock.
Several equities analysts have recently weighed in on LLY shares. BMO Capital Markets reissued a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a research report on Thursday, September 28th. Cowen restated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Goldman Sachs Group restated a “buy” rating and set a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Finally, Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their price objective for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $92.75.
Shares of Eli Lilly and Co (NYSE LLY) traded down $1.69 during mid-day trading on Tuesday, hitting $85.29. The company’s stock had a trading volume of 4,772,240 shares, compared to its average volume of 2,944,430. Eli Lilly and Co has a twelve month low of $74.00 and a twelve month high of $89.09. The stock has a market cap of $93,910.00, a PE ratio of 40.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the prior year, the business earned $0.88 EPS. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.64%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently 99.05%.
WARNING: “NEXT Financial Group Inc Has $678,000 Stake in Eli Lilly and Co (LLY)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/next-financial-group-inc-has-678000-stake-in-eli-lilly-and-co-lly/1809784.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with Analyst Ratings Network's FREE daily email newsletter.